Regulatory Milestone Adds to Fast-Track Designation Providing Further Potential Regulatory Advantages as Company Develops First-in-Class Mitochondrial Cell Therapy HAIFA, Israel, Oct. 15, 2025 (GLOBE NEWSWIRE) — Minovia Therapeutics Ltd. (“Minovia”…
Breakthrough Therapy Designation request has been submitted to FDA Company to request a Type B meeting with FDA in early 2026 to discuss requirements for a supplementary New Drug Application…
According to the agreement, SciSparc’s pharmaceuticals assets and equity stake in SciSparc Nutraceuticals Inc. are valued at approximately US$11.6 million TEL AVIV, Israel, Oct. 15, 2025 (GLOBE NEWSWIRE) — SciSparc…
• TRB-ILD1 granted U.S. Orphan Drug Designation by the FDA for the treatment of Idiopathic Pulmonary Fibrosis (IPF)• TRB-ONC1 granted U.S. Orphan Drug Designation by the FDA for the treatment…
AMX-883 uses Amphista’s Targeted Glue™ technology, inducing degradation of BRD9 through the recruitment of DCAF16, a completely distinct mechanism of action from cereblon- or VHL-based PROTACs. The nomination of AMX-883…
SAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) — Gyre Therapeutics (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today…
– Financing led by Engine Ventures with support from Amplify Partners, Starbloom Capital, Connecticut Innovations, and E1 Ventures– Proceeds to accelerate strategic partnerships and internal CNS development programs to showcase…
Zen Leaf is Located in Antwerp’s Norfolk & Western Train Depot Originally Built in 1880 and Listed on the National Register of Historic Places Located at 503 W. River Street,…
DURHAM, N.C., Oct. 15, 2025 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its third quarter 2025…
New safety and pharmacokinetic data from Phase 3 C-POST trial provide insights on an every 6-week dosing regimen of adjuvant Libtayo® (cemiplimab) in high-risk cutaneous squamous cell carcinoma TARRYTOWN, N.Y.,…